Legend Biotech
LEGN
218 hedge funds and large institutions have $2.98B invested in Legend Biotech in 2026 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 62 increasing their positions, 78 reducing their positions, and 26 closing their positions.
112% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 26
71% more funds holding in top 10
Funds holding in top 10: 7 → 12 (+5)
71% more capital invested
Capital invested by funds: $1.74B → $2.98B (+$1.24B)
35% more call options, than puts
Call options by funds: $21.3M | Put options by funds: $15.7M
14% more funds holding
Funds holding: 191 → 218 (+27)
3.54% more ownership
Funds ownership: 51.94% → 55.48% (+3.5%)
21% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 78
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$91.6M |
| 2 |
Goldman Sachs
New York
|
+$59.3M |
| 3 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$51.7M |
| 4 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$38.4M |
| 5 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$32.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
-$46.6M |
| 2 |
FBIL
First Beijing Investment Ltd
Hong Kong
|
-$41.5M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$40.4M |
| 4 |
Westfield Capital Management
Boston,
Massachusetts
|
-$36M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$21.8M |
LEGN Hedge Fund Activity: Q2 2026 in Review
218 institutional investors reported a position in Legend Biotech (LEGN) for Q2 2026, worth a combined $2.98B — up 71% from $1.74B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new LEGN positions and 26 closed out — a net gain of 29 holders — while 62 added to existing stakes and 78 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $91.6M. The largest seller was Two Sigma Investments, cutting an estimated $46.6M.
- 218 institutional investors held Legend Biotech (LEGN) as of Q2 2026, up from 191 in Q1 2026.
- Funds reported $2.98B of Legend Biotech stock for Q2 2026, up 71% quarter-over-quarter.
- 55 funds opened new Legend Biotech positions in Q2 2026 and 26 closed out, a net change of +29 holders.
- The largest Legend Biotech buyer in Q2 2026 was Fidelity Investments, an estimated $91.6M added.
- The largest Legend Biotech seller in Q2 2026 was Two Sigma Investments, an estimated $46.6M sold.
Based on aggregated 13F filings for Q2 2026.